About NX Prenatal
NX Prenatal is a Healthcare company based in Louisville (United States) founded in 2010 by Brian Brohman. Early warning blood tests for pregnancy complications are provided. It operates on a HealthTech model. NX Prenatal has raised $5.76 million across 5 funding rounds from investors including Johnson & Johnson Innovation. Its chief executive, as recorded, is Brian Brohman. NX Prenatal offers products and services including Preterm Birth Testing, Preeclampsia Detection, and Placenta Accreta Detection. Its focus areas include Medical Diagnostics and Maternal-Fetal Medicine. Its legal entity is NX Prenatal Inc. Its competitors include Sera Prognostics, Mirvie and DotLab; 2 of its 3 listed competitors have raised funding.
Company details
NX Prenatal is engaged in advancing maternal and fetal health by developing molecular blood tests. These tests are designed to provide early insights into conditions such as preterm birth, preeclampsia, and placenta accreta. The company collaborates with leading institutions to enable personalized healthcare delivery in the maternal-fetal medicine sector. Solutions are aimed at reducing complications and improving outcomes for mothers and babies through early detection and tailored health strategies.
- Headquarters Louisville, United States
- Founders Brian Brohman
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website nxprenatal.com
- Social LinkedIn
- Legal Name Nx Prenatal Inc.
- Total Equity Funding$5.76M (USD)
in 5 rounds
- Latest Funding Round$3.13M (USD), Series A
Aug 2023
- Investors
Products & Services of NX Prenatal
NX Prenatal offers a comprehensive portfolio of products and services, including Preterm Birth Testing, Preeclampsia Detection, and Placenta Accreta Detection.
Blood tests for preterm birth risk are provided early.
Early detection of preeclampsia risk is enabled through testing.
Technology for detecting placenta accreta is offered accurately.
Funding Insights of NX Prenatal
NX Prenatal has successfully raised a total of $5.76M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $3.13 million completed in August 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.76M
- Total Rounds 5
- Last Round Series A — $3.13M
- First Round $427,536
(Nov 2017)
- Investors Count 1
All 5 funding rounds of NX Prenatal with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2023 | $3.13M | Series A | – | – | – |
| Oct 2022 | Grant | – | – | ||
| Nov 2020 | $72,000 | Series A | – | – | – |
| May 2020 | $2.14M | Seed | – | – | – |
| Nov 2017 | $427,536 | Seed | – | – | – |
1 investors in total: 1 institutional.
Investors in NX Prenatal
NX Prenatal has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Johnson & Johnson Innovation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| jnjinnovation.com |
Investor details for NX Prenatal
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of NX Prenatal
13 people are tracked at NX Prenatal (3 in leadership, 10 in board & advisors).
| Name | Role | Group |
|---|---|---|
Brian Brohman | Co-Founder & Co-CEO | Leadership |
Gail S Page | Co-CEO | Leadership |
Brian D. Brohman | Co-founder, Director & Co-CEO | Leadership |
Robert G. Bonebrake | Advisor | Board & advisors |
Zhen Zhang | Advisor | Board & advisors |
Mary Lake Polan | Advisor | Board & advisors |
Thomas McElrath | Advisor | Board & advisors |
Alan Mack | Advisor | Board & advisors |
Robert C. Doss | Advisor | Board & advisors |
C. David Adair | Advisor | Board & advisors |
Daniel W. Chan | Advisor | Board & advisors |
Robert S. Saunders | Advisor | Board & advisors |
Danielle Scelfo | Advisor | Board & advisors |
Complete people profiles for NX Prenatal
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of NX Prenatal
3 dated milestones of NX Prenatal across 13 years, from founding to its latest funding, stage changes and deals.
- Founded NX Prenatal is founded.
- Funding First funding round of $428K.
- Funding Latest funding round, Series A, of $3.1M.
Competitors of NX Prenatal
NX Prenatal has 3 listed competitors in our database, 2 of them funded. They include Sera Prognostics, Mirvie and DotLab.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| seraprognostics.com | 2008 | Salt Lake, United States | 123 | Sera Prognostics is focused on women's health diagnostics. | ||
| mirvie.com | 2019 | San Francisco, United States | $113.7M | 35 | Non-invasive blood tests for prenatal fetal health predictions are offered. | |
| dotlab.com | 2016 | Branford, United States | $10M | 11 | Molecular diagnostic testing for endometriosis is provided via saliva-based biomarkers. |
Detailed competitors of NX Prenatal
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as NX Prenatal (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Nx Prenatal
Complete news archive for NX Prenatal
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about NX Prenatal
NX Prenatal was founded in 2010 and raised its 1st funding round 7 years after it was founded.
NX Prenatal is headquartered in Louisville, United States. It is registered at Louisville, Kentucky, United States.
Brian Brohman is the CEO of NX Prenatal, as recorded in our data. They have also founded this company.
NX Prenatal is a funded company, having raised a total of $5.76M across 5 funding rounds to date. The company's 1st funding round was a Seed of $427.54K, raised on Nov 2017.
NX Prenatal is engaged in advancing maternal and fetal health by developing molecular blood tests. These tests are designed to provide early insights into conditions such as preterm birth, preeclampsia, and placenta accreta. The company collaborates with leading institutions to enable personalized healthcare delivery in the maternal-fetal medicine sector. Solutions are aimed at reducing complications and improving outcomes for mothers and babies through early detection and tailored health strategies.
NX Prenatal's top competitors include Mirvie, DotLab and Sera Prognostics.
NX Prenatal offers Preterm Birth Testing, Preeclampsia Detection, and Placenta Accreta Detection.
NX Prenatal has 1 investor. Key investors include Johnson & Johnson Innovation.
NX Prenatal operates through Nx Prenatal Inc..